The New England journal of medicine, 2022-01, Vol.386 (4), p.351-363
- Tilly, Hervé
- Morschhauser, Franck
- Sehn, Laurie H
- Friedberg, Jonathan W
- Trněný, Marek
- Sharman, Jeff P
- Herbaux, Charles
- Burke, John M
- Matasar, Matthew
- Rai, Shinya
- Izutsu, Koji
- Mehta-Shah, Neha
- Oberic, Lucie
- Chauchet, Adrien
- Jurczak, Wojciech
- Song, Yuqin
- Greil, Richard
- Mykhalska, Larysa
- Bergua-Burgués, Juan M
- Cheung, Matthew C
- Pinto, Antonio
- Shin, Ho-Jin
- Hapgood, Greg
- Munhoz, Eduardo
- Abrisqueta, Pau
- Gau, Jyh-Pyng
- Hirata, Jamie
- Jiang, Yanwen
- Yan, Mark
- Lee, Calvin
- Flowers, Christopher R
- Salles, Gilles
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Tilly, Hervé
- Morschhauser, Franck
- Sehn, Laurie H
- Friedberg, Jonathan W
- Trněný, Marek
- Sharman, Jeff P
- Herbaux, Charles
- Burke, John M
- Matasar, Matthew
- Rai, Shinya
- Izutsu, Koji
- Mehta-Shah, Neha
- Oberic, Lucie
- Chauchet, Adrien
- Jurczak, Wojciech
- Song, Yuqin
- Greil, Richard
- Mykhalska, Larysa
- Bergua-Burgués, Juan M
- Cheung, Matthew C
- Pinto, Antonio
- Shin, Ho-Jin
- Hapgood, Greg
- Munhoz, Eduardo
- Abrisqueta, Pau
- Gau, Jyh-Pyng
- Hirata, Jamie
- Jiang, Yanwen
- Yan, Mark
- Lee, Calvin
- Flowers, Christopher R
- Salles, Gilles
- Titel
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
- Ist Teil von
- The New England journal of medicine, 2022-01, Vol.386 (4), p.351-363
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The treatment outcome for diffuse large B-cell lymphoma has not been improved in nearly 20 years. However, the replacement of vincristine in R-CHOP with polatuzumab vedotin, an anti-CD79b antibody linked to emtansine, led to a progression-free survival benefit over R-CHOP at 2 years (76.7% vs. 70.2%), with a similar safety profile.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2115304Titel-ID: cdi_hal_primary_oai_HAL_hal_04185653v1
- Format
- –
- Schlagworte
- Adult, Aged, Antibodies, Monoclonal - administration & dosage, Antibodies, Monoclonal - adverse effects, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, B-cell lymphoma, Cell surface, Cyclophosphamide, Cyclophosphamide - adverse effects, Cyclophosphamide - therapeutic use, Death, Disease prevention, Double-Blind Method, Doxorubicin, Doxorubicin - adverse effects, Doxorubicin - therapeutic use, Female, Hematology, Humans, Hypothesis testing, Immunoconjugates - administration & dosage, Immunoconjugates - adverse effects, Immunotherapy, Leukemia, Life Sciences, Lymphocytes B, Lymphoma, Lymphoma, Large B-Cell, Diffuse - drug therapy, Lymphoma, Large B-Cell, Diffuse - mortality, Male, Medical prognosis, Middle Aged, Monoclonal antibodies, Oncology, Prednisone, Prednisone - adverse effects, Prednisone - therapeutic use, Progression-Free Survival, Radiation therapy, Risk assessment, Rituximab, Rituximab - adverse effects, Rituximab - therapeutic use, Statistical analysis, Targeted cancer therapy, Tomography, Treatments in Oncology, Vincristine, Vincristine - adverse effects, Vincristine - therapeutic use